VIDEO: Indirect comparison yields similar risk, benefit profiles among UC treatment
Click Here to Manage Email Alerts
LAS VEGAS – Matching-adjusted indirect comparisons found a positive benefit-risk profile for ozanimod vs. adalimumab and a comparable profile for ozanimod vs. vedolizumab.
“This is not doing head-to-head trials. This is using a methodology which allows you to look at like patient populations and comments on the benefit-risk profile,” Marla Dubinsky, MD, of the Icahn School of Medicine, said in a video exclusive with Healio Gastroenterology. “It was great to see how we’re going to be thinking as new targets come. ... We’ll keep doing these modified comparisons in the absence of head-to-head, which will help us determine maybe the sequence of therapies.”
Collapse
Dubinsky M, et al. Abstract: Comparative efficacy and safety of ozanimod vs. adalimumab and vedolizumab in patients with moderately to severely active ulcerative colitis. Presented at: ACG Annual Scientific Meeting; Oct. 22-27, 2021. Las Vegas (hybrid meeting).
Read more about
Click Here to Manage Email Alerts